CN110917142A - Florfenicol soluble powder medicine - Google Patents
Florfenicol soluble powder medicine Download PDFInfo
- Publication number
- CN110917142A CN110917142A CN201811097850.2A CN201811097850A CN110917142A CN 110917142 A CN110917142 A CN 110917142A CN 201811097850 A CN201811097850 A CN 201811097850A CN 110917142 A CN110917142 A CN 110917142A
- Authority
- CN
- China
- Prior art keywords
- florfenicol
- soluble powder
- citric acid
- anhydrous
- anhydrous citric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a florfenicol soluble powder medicament, and relates to the technical field of veterinary medicaments. The florfenicol soluble powder medicine comprises the following components: florfenicol, anhydrous citric acid, trimethoprim lactate and anhydrous glucose. The florfenicol soluble powder medicament can be quickly dissolved in water to achieve the purpose of solubility, has the advantages of convenient administration and quick response, and enhances the treatment effect of the whole powder and the medicament effect by adopting the florfenicol and the synergist for combined administration.
Description
Technical Field
The invention relates to the technical field of veterinary medicines, in particular to a florfenicol soluble powder medicine.
Background
Florfenicol is used as a third-generation fluorophlomycin broad-spectrum antibacterial special for veterinarians and is mainly used for preventing and treating bacterial diseases of livestock, poultry, fishes and the like caused by sensitive bacteria.
Florfenicol has low solubility, is water-insoluble powder, influences the development of soluble powder to a certain extent, has low absorption and bioavailability in animal bodies, is usually mixed into feed for administration during administration, has single administration route, limits the full play of drug effect, has poor curative effect due to inconvenient administration, causes no appetite when poultry and livestock suffer from diseases, and is not favorable for popularization and application in breeding production.
Disclosure of Invention
In order to solve the technical problems, the invention provides a florfenicol soluble powder medicament and a preparation method thereof.
The technical scheme of the invention is as follows: a florfenicol soluble powder medicine comprises the following components in every 100g of medicine: 9-11g of florfenicol, 9-11g of anhydrous citric acid, 1.5-2.5g of lactic acid trimethoprim and the balance of anhydrous glucose.
Preferably, the florfenicol soluble powder medicament comprises the following components in every 100g of medicament: 10g of florfenicol, 10g of anhydrous citric acid, 2g of trimethoprim lactate and the balance of anhydrous glucose.
The invention discloses a method for preparing a florfenicol soluble powder medicament, which comprises the following steps: respectively crushing and sieving florfenicol, anhydrous citric acid and trimethoprim lactate, weighing the florfenicol, the anhydrous citric acid and the trimethoprim lactate according to the prescription requirement, adding anhydrous glucose with the same weight as the sum of the three components, premixing for 15 minutes by a dispersion method, fully mixing with the rest anhydrous glucose for 1 hour, and uniformly mixing to obtain the florfenicol soluble powder medicament.
The florfenicol and the synergist are combined to enhance the treatment effect of the whole powder. Meanwhile, in the specific preparation process, the florfenicol and the anhydrous citric acid are reasonably proportioned and ground, so that the defect of low water solubility of the florfenicol is overcome, the florfenicol can be completely dissolved into water, meanwhile, the curative effect of the florfenicol can be enhanced by the trimethoprim lactate, the folic acid metabolism of bacteria can be subjected to double negative interruption, the effect of the florfenicol medicine reaches several times to dozens of times, the generation of drug-resistant strains can be reduced, and the drinking agent prepared from the florfenicol and the anhydrous citric acid is convenient to use, remarkable in curative effect and particularly remarkable in curative effect on respiratory system infection. The preparation method is simple and easy to implement and is suitable for industrial production and application.
Detailed Description
The present invention will be further described with reference to the following specific examples.
Example 1
A florfenicol soluble powder medicine comprises the following components in every 100g of medicine: 9g of florfenicol, 9g of anhydrous citric acid, 1.5g of trimethoprim lactate and the balance of anhydrous glucose.
The method for preparing the florfenicol soluble powder medicament comprises the following steps: respectively crushing and sieving florfenicol, anhydrous citric acid and trimethoprim lactate, weighing 9g of florfenicol, 9g of anhydrous citric acid and 1.5g of trimethoprim lactate, adding 19.5g of anhydrous glucose, premixing for 15 minutes according to a dispersion method, adding the balance of anhydrous glucose, fully mixing for 1 hour, and uniformly mixing to obtain the florfenicol soluble powder medicament in the embodiment 1 of the invention.
Example 2
A florfenicol soluble powder medicine comprises the following components in every 100g of medicine: 10g of florfenicol, 10g of anhydrous citric acid, 2g of trimethoprim lactate and the balance of anhydrous glucose.
The method for preparing the florfenicol soluble powder medicament comprises the following steps: respectively crushing and sieving florfenicol, anhydrous citric acid and trimethoprim lactate, weighing 10g of florfenicol, 10g of anhydrous citric acid and 2g of trimethoprim lactate, adding 22g of anhydrous glucose, premixing for 15 minutes according to a dispersion method, adding the balance of anhydrous glucose, fully mixing for 1 hour, and uniformly mixing to obtain the florfenicol soluble powder medicament of the embodiment 2.
Example 3
A florfenicol soluble powder medicine comprises the following components in every 100g of medicine: 11g of florfenicol, 11g of anhydrous citric acid, 2.5g of trimethoprim lactate and the balance of anhydrous glucose.
The method for preparing the florfenicol soluble powder medicament comprises the following steps: respectively crushing and sieving florfenicol, anhydrous citric acid and trimethoprim lactate, weighing 11g of florfenicol, 11g of anhydrous citric acid and 2.5g of trimethoprim lactate, adding 24.5g of anhydrous glucose, premixing for 15 minutes according to a dispersion method, adding the balance of anhydrous glucose, fully mixing for 1 hour, and uniformly mixing to obtain the florfenicol soluble powder medicament in the embodiment 3 of the invention.
Comparative example 1 of chinese invention patent 201510284970.3
The soluble florfenicol powder consists of the following components in percentage by weight: florfenicol 10%, polyvinylpyrrolidone K305%, polyethylene glycol 400010%, frankincense from pig 5%, and glucose 70% (the content of each component is calculated by the weight of soluble florfenicol powder being 100 kg).
The method for preparing the soluble florfenicol powder comprises the following steps:
1) weighing the components according to the weight percentage, weighing the florfenicol, the polyvinylpyrrolidone K30, the polyethylene glycol 4000 and the pig milk fragrance according to the weight percentage in the formula, crushing and sieving by a 80-mesh sieve;
2) sequentially adding the materials in the step 1) into a three-dimensional mixer for first mixing for 30 minutes to obtain a first mixture;
3) crushing glucose, sieving with a 80-mesh sieve, adding into a three-dimensional mixer, and mixing with the first mixture for a second time for 40 minutes to obtain a second mixture;
4) and (5) carrying out quality inspection on the second mixture, and subpackaging to obtain a finished product.
Test example 1 clinical efficacy test
1. Test animal
The clinical experimental animals select 200 sick pigs which are naturally infected with actinobacillus pleuropneumoniae in a certain pig farm and are diagnosed. Variety: three-way hybrid pigs without any drug treatment. Diagnosis standard of sick pigs: the outbreak of disease in pigs, the increase of body temperature (41-42 ℃), dyspnea, acceleration, cough or abdominal respiration, short-term diarrhea and vomiting symptoms, mental depression and inappetence. Representing the characteristic cellulolytic necrotizing and hemorrhagic pneumonia of the lung pleura of the autopsy pig and the cellulose pleurisy. The lung has necrotic foci, cheese-like lesions, cavities, etc.
The sick pigs are separately fed, and fed with complete feed, and divided into 5 groups according to weight, wherein each group has 40 pigs, the average weight of the pigs is 41 + -0.5 kg, the feeding environment of the 5 groups is completely consistent, the test time is 3 days, and the pigs are observed for 3 days after medicine withdrawal.
2. Test drugs
Test 1 group was fed with the product obtained in example 1 of the present invention, test 2 group was fed with the product obtained in example 2 of the present invention, test 3 group was fed with the product obtained in example 3 of the present invention, and control group was fed with the product obtained in comparative example 1 of the present invention, and each group was fed with 100g of the product obtained in each example, added with water and stirred until completely dissolved once a day. The blank control group was fed the complete feed alone without the drug.
3. Criteria for judging therapeutic effects
And (3) curing: after injection administration for 3 days, the mental state, appetite, respiration and body temperature of the test pigs are all recovered to be normal, and no relapse occurs after the administration is stopped. And calculating the cure rate according to the proportion of the number of the cured heads in the group of heads.
The method has the following advantages: after 3 days of injection administration, the pig is proved to have obviously improved mental state, increased appetite, mild abdominal respiration or cough. The sum of the effective number and the curative number is the total effective number, and the total effective rate is calculated according to the proportion of the total effective number in the test number.
And (4) invalidation: after 3 days of injection administration, the symptoms of the test pigs such as spirit, appetite, respiration, body temperature and the like still do not improve or even worsen the dead. Calculating the inefficiency according to the proportion of the number of invalid heads to the number of test heads in the set.
4. Test results
After three days of treatment trials, the results of clinical comparative trials on the treatment of porcine contagious pleuropneumonia for each trial drug group are shown in table 1.
TABLE 1 clinical comparative test results of the treatment of porcine contagious pleuropneumonia by each test drug group
As can be seen from Table 1, the cure rates of the test groups 1 to 3 of the invention respectively reach 90%, 95% and 92.5%, the total effective rates respectively reach 97.5%, 100% and 100%, and are remarkably higher than the cure rate of the control group by 62.5% and the total effective rate by 80%, which shows that the florfenicol soluble powder medicine of the invention has remarkable treatment effect, and the combined medication of the florfenicol and the synergist enhances the treatment effect of the whole powder. The florfenicol soluble powder medicine is convenient to use, obvious in curative effect, simple and feasible in preparation method and suitable for industrial production and application.
Claims (3)
1. The florfenicol soluble powder medicine is characterized in that every 100g of medicine comprises the following components: 9-11g of florfenicol, 9-11g of anhydrous citric acid, 1.5-2.5g of lactic acid trimethoprim and the balance of anhydrous glucose.
2. The florfenicol soluble powder drug as claimed in claim 1 wherein the composition per 100g of drug is: 10g of florfenicol, 10g of anhydrous citric acid, 2g of trimethoprim lactate and the balance of anhydrous glucose.
3. The florfenicol soluble powder drug as claimed in claim 1 wherein the drug is prepared by the following process: respectively crushing and sieving florfenicol, anhydrous citric acid and trimethoprim lactate, weighing the florfenicol, the anhydrous citric acid and the trimethoprim lactate according to the prescription requirement, adding anhydrous glucose with the same weight as the sum of the three components, premixing for 15 minutes by a dispersion method, fully mixing with the rest anhydrous glucose for 1 hour, and uniformly mixing to obtain the florfenicol soluble powder medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097850.2A CN110917142A (en) | 2018-09-20 | 2018-09-20 | Florfenicol soluble powder medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811097850.2A CN110917142A (en) | 2018-09-20 | 2018-09-20 | Florfenicol soluble powder medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110917142A true CN110917142A (en) | 2020-03-27 |
Family
ID=69855219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811097850.2A Pending CN110917142A (en) | 2018-09-20 | 2018-09-20 | Florfenicol soluble powder medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110917142A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111569045A (en) * | 2020-06-17 | 2020-08-25 | 江西派尼生物药业有限公司 | Florfenicol soluble powder medicine |
| CN111588698A (en) * | 2020-06-23 | 2020-08-28 | 南京大方生物工程有限公司 | Florfenicol powder for improving water solubility and preparation method and application thereof |
-
2018
- 2018-09-20 CN CN201811097850.2A patent/CN110917142A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111569045A (en) * | 2020-06-17 | 2020-08-25 | 江西派尼生物药业有限公司 | Florfenicol soluble powder medicine |
| CN111588698A (en) * | 2020-06-23 | 2020-08-28 | 南京大方生物工程有限公司 | Florfenicol powder for improving water solubility and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101843586B (en) | Water-soluble micro powder containing florfenicol and preparation method thereof | |
| CN102415991B (en) | Enrofloxacin long-acting injection and preparation method thereof | |
| CN102670516A (en) | Tilmicosin soluble powder and preparation method thereof | |
| CN104922073A (en) | Soluble florfenicol powder and preparation method thereof | |
| CN101496811B (en) | Soluble and stable tilmicosin composition | |
| CN110917142A (en) | Florfenicol soluble powder medicine | |
| CN110917141A (en) | Method for preparing florfenicol soluble powder medicament | |
| CN101829082A (en) | Method for preparing veterinary injection of spectinomycin hydrochloride and lincomycin hydrochloride | |
| CN104800167A (en) | Florfenicol soluble powder and preparation method thereof | |
| CN105534912A (en) | High-stability valnemulin hydrochloride soluble powder and uses thereof | |
| CN107837235A (en) | It is coated with the preparation method of Enrofloxacin soluble powder | |
| EP3288391B1 (en) | Feed supplement additive | |
| CN101450061A (en) | Soluble powder for treating poultry bacterial infection | |
| CN101590019A (en) | Soluble compound doxycycline hyclate powder for animals and preparation method thereof | |
| CN106620668A (en) | Compound tilmicosin solid dispersing agent and preparation method thereof | |
| CN102755337B (en) | Compound florfenicol injection and preparation method thereof | |
| CN101450065A (en) | Powder for treating livestock and poultry mycoplasma infection | |
| CN106362159A (en) | Molecular skeleton type tilmicosin sustained release preparation and preparation method thereof | |
| CN103211818A (en) | Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN101301274B (en) | Compound mequindox soluble powder for animals and preparation thereof | |
| CN111759854A (en) | Injection composition for treating respiratory diseases of animals and preparation method thereof | |
| CN108261440B (en) | Soft capsule for treating postpartum endometritis of sow and preparation method thereof | |
| CN104839458A (en) | Polyhexamethylene guanidine medicated feed additive | |
| CN108670948A (en) | A kind of nanoscale micro-capsule unimolecule Betagen Solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200327 |